Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Alexandra Dreyzin, Yihua Cai, Kyu Lee Han, Michaela Prochazkova, Jennifer Webb, Keri Toner, Kathryn Bushnell, Bonnie Yates, Ping Jin, David F. Stroncek, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2024-199264

Published: 2024

Journal Articles

Adding Hydroxyurea to Chronic Transfusion for Sickle Cell Anemia Reduces Transfusion Burden: Final Results of the HAT Prospective Trial

Robert Sheppard Nickel, Stefanie Margulies, Brittany Frazer, Allistair Abraham, Naomi Luban, Jennifer Webb

Blood (2021) 138 (Supplement 1): 2036.

https://doi.org/10.1182/blood-2021-144453

Published: 2021

Journal Articles

Pediatric Sickle Cell Disease and the COVID-19 Pandemic: A Year in Review at Children's National Hospital

Olufunke Y. Martin, Deepika S. Darbari, Stefanie Margulies, Robert Sheppard Nickel, Alexis Leonard, Barbara Speller-Brown, Brenda Martin, Jennifer Webb, Suvankar Majumdar, Matthew Sharron, Andrew D. Campbell

Blood (2021) 138 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2021-149808

Published: 2021

Journal Articles

Impact of Universal Irradiation on Chronic Transfusion for Sickle Cell Disease

Gabriel Salinas Cisneros, MD, Naomi Luban, MD, Jennifer Webb, MD, Robert Sheppard Nickel, MDMSc

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-140828

Published: 2020

Journal Articles

Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic

Robert Sheppard Nickel, Stefanie Margulies, Brittany Frazer, Naomi L. C. Luban, Jennifer Webb

Blood (2020) 135 (25): 2320–2322.

https://doi.org/10.1182/blood.2020006582

Published: 2020

Journal Articles

Effects of Combination Hydroxyurea and Chronic Red Blood Cell Transfusion Therapy on the Immune Parameters of Patients with Sickle Cell Disease

Mahogany Oldham, Gelina Sani, Stefanie Margulies, MS, Jennifer Webb, MD MSCE, Robert Sheppard Nickel, MDMSc, Allistair Abraham, MD

Blood (2019) 134 (Supplement_1): 4840.

https://doi.org/10.1182/blood-2019-126180

Published: 2019

Journal Articles

Retrospective Analysis of Compliance and Efficacy of a Novel Formulation of Deferasirox

Jamila Holloway, BS, Chisom Okezue, Jennifer Webb, MD

Blood (2018) 132 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2018-99-118810

Published: 2018

Journal Articles

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation

Courtney W. Johnson, MD MSc, Suvankar Majumdar, MBCHB, Andrew D. Campbell, MD, Suresh Magge, MD, Deepika S. Darbari, MD, Jennifer Webb, MD, Yaser A. Diab, MBBS, Robert Sheppard Nickel, MDMSc, Barbara Speller-Brown, DNP, CPNP-BC, Jessica Carpenter, MD, Allistair Abraham, MD

Blood (2018) 132 (Supplement 1): 1098.

https://doi.org/10.1182/blood-2018-99-118693

Published: 2018

Journal Articles

Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial

Russell E. Ware, MD PhD, Adam Lane, PhD, William H Schultz, MHS PA, Hamayun Imran, MD, Margaret T. Lee, MD, Matthew M Heeney, MD, Clark Brown, MD PhD, Lori Luchtman-Jones, MD, Jennifer Webb, MD, Sherron Jackson, MD, Banu Aygun, MD, Scott T. Miller, MD, Jennifer A Rothman, MD, Alexis A. Thompson, MD MPH, Judy Luden, CCRP, Barry R Davis, MD PhD, Robert J. Adams, MD

Blood (2016) 128 (22): 1019.

https://doi.org/10.1182/blood.V128.22.1019.1019

Published: 2016

Journal Articles

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif S. Farag, John C. Byrd

Blood (2005) 105 (1): 289–291.

https://doi.org/10.1182/blood-2004-02-0651

Published: 2005

Journal Articles

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, Jennifer Harbison, Jennifer Webb, Mollie Moran, Margaret Lucas, Thomas Lin, Marcy L. Hackbarth, John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd

Blood (2004) 103 (9): 3278–3281.

https://doi.org/10.1182/blood-2003-10-3729

Published: 2004

NARROW

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Adding Hydroxyurea to Chronic Transfusion for Sickle Cell Anemia Reduces Transfusion Burden: Final Results of the HAT Prospective Trial

Pediatric Sickle Cell Disease and the COVID-19 Pandemic: A Year in Review at Children's National Hospital

Impact of Universal Irradiation on Chronic Transfusion for Sickle Cell Disease

Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic

Effects of Combination Hydroxyurea and Chronic Red Blood Cell Transfusion Therapy on the Immune Parameters of Patients with Sickle Cell Disease

Retrospective Analysis of Compliance and Efficacy of a Novel Formulation of Deferasirox

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation

Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only